Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10914584 | Molecular Oncology | 2016 | 13 Pages |
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type and is characterized by a dismal prognosis due to late diagnosis, local tumor invasion, frequent distant metastases and poor sensitivity to current therapy. In this context, circulating tumor cells and circulating tumor DNA constitute easily accessible blood-borne tumor biomarkers that may prove their clinical interest for screening, early diagnosis and metastatic risk assessment of PDAC. Moreover these markers represent a tool to assess PDAC mutational landscape. In this review, together with key biological findings, we summarize the clinical results obtained using “liquid biopsies” at the different stages of the disease, for early and metastatic diagnosis as well as monitoring during therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Francesca Riva, Oleksii I. Dronov, Dmytro I. Khomenko, Florence Huguet, Christophe Louvet, Pascale Mariani, Marc-Henri Stern, Olivier Lantz, Charlotte Proudhon, Jean-Yves Pierga, Francois-Clement Bidard,